These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33914089)

  • 1. [Secondary stroke prevention after TIA or ischemic stroke].
    Diener HC; Nickenig G
    Herz; 2021 Jun; 46(3):293-302. PubMed ID: 33914089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar.
    Diener HC; Hankey GJ
    J Am Coll Cardiol; 2020 Apr; 75(15):1804-1818. PubMed ID: 32299593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials.
    Vaduganathan M; Qamar A; Gupta A; Bajaj N; Golwala HB; Pandey A; Bhatt DL
    Am J Med; 2018 May; 131(5):575-577. PubMed ID: 29229471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
    Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J
    Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding patent foramen ovale closure to antiplatelet drugs reduced ischemic stroke after cryptogenic stroke.
    Alberts MJ
    Ann Intern Med; 2018 Jan; 168(2):JC6. PubMed ID: 29335718
    [No Abstract]   [Full Text] [Related]  

  • 8. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Di Napoli M; Silvestrini M
    Cerebrovasc Dis; 2018; 45(5-6):193-203. PubMed ID: 29649819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
    Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
    N Engl J Med; 2012 Mar; 366(11):991-9. PubMed ID: 22417252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Asmarats L; Côté M; Rodés-Cabau J
    J Am Coll Cardiol; 2019 Jan; 73(3):278-287. PubMed ID: 30678757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA.
    Dia A; Cifu AS; Shah AP
    JAMA; 2021 Jan; 325(1):81-82. PubMed ID: 33399834
    [No Abstract]   [Full Text] [Related]  

  • 12. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
    Søndergaard L; Kasner SE; Rhodes JF; Andersen G; Iversen HK; Nielsen-Kudsk JE; Settergren M; Sjöstrand C; Roine RO; Hildick-Smith D; Spence JD; Thomassen L;
    N Engl J Med; 2017 Sep; 377(11):1033-1042. PubMed ID: 28902580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale.
    Schuchlenz HW; Weihs W; Berghold A; Lechner A; Schmidt R
    Int J Cardiol; 2005 May; 101(1):77-82. PubMed ID: 15860387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of secondary atrial fibrillation following percutaneous foramen ovale closure for cryptogenic stroke using an insertable cardiac monitor: a case report].
    Egashira S; Doijiri R; Endo H; Kimura N; Nakajima Y; Morino Y; Kikuchi T
    Rinsho Shinkeigaku; 2022 Oct; 62(10):787-792. PubMed ID: 36184419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
    Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
    Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Sagris D; Makaritsis K; Vemmos K; Steiner T; Michel P
    Stroke; 2018 Feb; 49(2):412-418. PubMed ID: 29335335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale.
    Casaubon L; McLaughlin P; Webb G; Yeo E; Merker D; Jaigobin C
    Can J Neurol Sci; 2007 Feb; 34(1):74-80. PubMed ID: 17352351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of stroke recurrence between antiplatelet and closure therapy in cryptogenic stroke patients with patent foramen ovale and its influencing factors.
    Zhang C; Zheng L; Zhang Y; Guo H; Chi J
    Eur J Intern Med; 2020 Aug; 78():149-151. PubMed ID: 32307231
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
    Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
    Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.